Over the last decade latex-induced asthma (LIA) has been reported as a significant health problem.
RuzamÔ (R) is peptide complex isolated from the thermophilic strain of Staph. aureus, capable to suppress allergic inflammatory response . The aim of the study was to assess clinical efficacy and safety of R treatment in LIA patients.
Methods: Opened controlled randomized 10-week study involved 23 patients (15 females and 8 males aged 24 to 43 yrs, FEV1=75.8±2.1%) with intermittent and mild persistent LIA. Hypersensitivity to latex was detected by medical examination, questionnaire, skin prick tests (SPT) and RAST with latex extract (ALK, Denmark). All the subjects were treated with R (intradermal 0.15-0.2ml once a week) during 10 weeks. The control group (CG) consisted of 20 subjects (14 females and 6 males aged 23 to 45 yrs, FEV1= 76.2±1.4%) with intermittent and mild persistent LIA used basic treatment only. Efficacy of R treatment was studied by changes of clinical symptoms, PEF, b2-agonists use, FEV1 and exhaled nitric oxide (NOexh) level.
Results: 17 (73.9%) patients had significant decrease in mild daily respiratory allergic symptoms and need of b2-agonists after 6 to 7 weeks of treatment (p<0.005). Significant improvement in PEF and lung function parameters (p<0.005) were registered after 10 weeks of therapy. The mean values of NOexh became lower and correlated with the changes in FEV1 (r=0.67, p<0.003). R tolerance was satisfactory in all the patients. No such differences were found in the CG.
Conclusion: These results demonstrate clinical efficacy and safety of R therapy in patients with LIA.